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Aims We sought to determine the association between two major biomarkers, the inactive N-terminal fragment of brain
natriuretic peptide (NT-proBNP) and tissue inhibitor of metalloproteinase-1 (TIMP-1) and long-term cardiovascular
outcomes in a cohort of subjects who had a myocardial infarction or unstable angina 3–36 months previously.
Methods
and results
Plasma NT-proBNP and TIMP-1 were measured in a nested case control study of 250 randomly matched subject
pairs enrolled in the long-term intervention with pravastatin in ischaemic disease (LIPID) and LIPID extended
follow-up studies. Cases (n ¼ 250) were deﬁned as those who had a cardiovascular death, non-fatal myocardial infarc-
tion or stroke during the studies. Controls (n ¼ 250) remained event-free for the same follow-up duration (average
2.5 years) as the matched cases. The relationships between cases and plasma NT-proBNP and TIMP-1 were adjusted
for the LIPID risk score, treatment allocation and other biomarkers (CRP, IL-6 and white cell count), and examined
using a multivariable conditional logistic regression model. NT-proBNP levels were signiﬁcantly higher in the cases
than in the controls [389 (152–864) vs. 198 (93–416) pg/mL, median (25%–75% percentiles), P , 0.001]. The
odds ratio (OR) of recurrent cardiovascular events in individuals in the highest quartile was three times higher
than those in the lowest quartile (95% conﬁdence interval (CI) 1.8–5.1; P , 0.001). Similarly, TIMP-1 levels were sig-
niﬁcantly higher among cases compared with controls (806 vs. 736 pg/mL, median: highest vs. lowest quartile: OR 2.8,
95% CI 1.6–4.7; P , 0.001). After adjustment for the LIPID risk score, treatment with pravastatin and other bio-
markers, both NT-proBNP and TIMP-1 predicted cardiovascular events signiﬁcantly and independently of each other.
Conclusion The study suggests that in subjects with stable ischaemic disease, NT-proBNP and TIMP-1 are independent predictive
markers of coronary heart disease outcome.
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 Introduction
Results from large prospective cohort studies suggest that risk of
future occurrence of coronary heart disease (CHD) events can
be estimated
1,2 and that strategies to inﬂuence major modiﬁable
risk factors may result in improved mortality and morbidity. Estab-
lished risk factors account for a substantial proportion of the risk
of CHD, yet prediction of future cardiovascular disease (CVD)
events is less certain. Parameters reﬂecting left ventricular dysfunc-
tion are amongst the best predictors of recurrent CVD events.
3
Attempts to improve predictive accuracy of tests for CVD
events have included inﬂammatory mediators and other bio-
markers that reﬂect aspects of atherothrombotic processes that
underlie recurrent events. In the long-term intervention with pra-
vastatin in ischaemic disease (LIPID) study
4 we have observed that
total white blood cell (WBC) count but not C-reactive protein
(CRP), displayed independent predictive power. Inﬂammatory
markers also participate in the process of ventricular remodelling
that may occur as a component of CHD or some of its risk factors.
Tissue inhibitor of metalloproteinase-1 (TIMP-1) and N-terminal
pro-brain natriuretic peptide (NT-proBNP) have in common that
both have been correlated directly with major CVD risk factors:
TIMP-1 in the Framingham Offspring Study
5 and NT-proBNP in risk
stratiﬁcation in the AtheroGene Study
6 both expressed damaged
myocardium.
7,8Changesintheintegrityofthemyocardialextracellu-
lar matrix
9 as well as in processes that regulate the balance between
atheromatous plaque dissolution and stability can lead to increased
TIMP-1 expression.
10 Myocardial stretch associated with changes in
ventricularfunctionstimulatessecretionofBNP,whichissynthesized
as an inactive prohormone and released from the ventricle as active
BNP hormone and an inactive N-terminal fragment (NT-proBNP).
TheprognosticuseofBNP hasbeenassessedinheartfailure,
11myo-
cardialischaemia
12andotherclinicalsettings.
13Tworecentprospec-
tive longitudinal studies demonstrated that raised plasma
NT-proBNP in stable CHD was related to long-term mortality.
14,15
TIMP-1 has also been shown to be abnormally elevated in the
plasma of patients with acute coronary syndromes
16,17 and in a
2-yearfollow-upofmenwhohadundergonecoronaryangiography.
18
The relative strengths of the associations between BNP (or
NT-proBNP) and of TIMP-1 as independent predictors of recur-
rent CVD events in patients with established CHD are unknown.
Of further interest is whether treatment with cholesterol lowering
agents such as pravastatin inﬂuences predictive powers of
NT-proBNP and TIMP-1. These issues were examined in a
cohort of 500 patients with pre-existing CHD who were enrolled
in the much larger LIPID and LIPID extended follow-up studies and
who were prospectively monitored for recurrent CVD events
of myocardial infarction and cardiovascular death. The potential
confounding effects of conventional risk factors and other
inﬂammatory biomarkers (CRP and IL-6) were also analysed.
Methods
Study population
The design of the LIPID Study has been described in detail previously.
People aged 31–75 years, who had suffered a myocardial infarction or
hospital admission for unstable angina 3–36 months previously
entered the LIPID trial if their plasma total cholesterol was 4.0–
7.0 mmol/L (155–271 mg/dL) and fasting triglycerides ,5.0 mmol/L
(,445 mg/dL). Patients were screened in 87 centres in Australia and
New Zealand. After an 8-week placebo run-in phase, 9014 patients
were randomly allocated to receive pravastatin 40 mg daily or match-
ing placebo. After closure of the placebo-controlled trial and after a
mean follow-up of 6 years, all patients still alive were seen in clinic
visits (wherever possible) and offered open-label pravastatin 40 mg
daily for a further 2 years, irrespective of the original assigned
therapy. All deaths, myocardial infarctions, and strokes were
reviewed by outcome-assessment committees whose members had
no knowledge of the treatment assignment at the commencement of
the study.
A study of 500 patients was designed to be an initial pilot investi-
gation to obtain data on potential biomarkers that could form the
basis of measurements in the total cohort. The primary analysis was
to determine which biomarkers were strongly predictive of future
CVD events based on the strengths of their associations on initial uni-
variable analyses. In the LIPID trial sampling of blood was made at base-
line and annually during the 6 years of the blinded phase. Since the
baseline and 1-year samples have been conserved for analysis of the
entire cohort, blood samples that were collected from patients
during the placebo-controlled trial and 4–6 years after randomization
have been used for this study. Apart from the ﬁrst 2-yearly samples,
adequate volumes for the pilot study were available in years four to
six. Subjects were randomly selected using a nested case control
design with 250 cases and 250 controls. A case was deﬁned as a
patient who had a cardiovascular event at some time point after the
collection date of the sample of that patient and during the remainder
of the placebo-controlled or open label phases of the LIPID study. This
time averaged to 2.5 years. A cardiovascular event was deﬁned as car-
diovascular death, non-fatal myocardial infarction or stroke. The time
of the event refers to the earliest event during this time period (if
more than one occurred) and was measured from the blood collection
date. For each case a matched control was selected at random from
among all the remaining eligible patients who had not had a cardiovas-
cular event during the same length of follow-up time from blood col-
lection as the matched case.
Laboratory methods
Blood was drawn after a 12-h fast into EDTA tubes. Samples were
stored in liquid nitrogen at 2708C until analysis. Plasma NT-proBNP
was measured using an electrochemiluminescence sandwich immu-
noassay (ECLIA, Roche Diagnostics, Mannheim, Germany) on an
Elecsys System 2010. Intra- and interassay precision for the
luminescence-sandwich-immunoassay were 0.8–3% and 2.2–5.8%,
respectively. The linear range of detection of this assay was 5–
35 000 pg/mL; cross-reactivity with brain natriuretic peptide and
atrial natriuretic peptide was less than 0.001%. Plasma TIMP-1 was
measured by single determination using a commercially available
two-site ELISA method (Amersham Biosciences Europe). The ELISA
determines free TIMP-1 and TIMP-1 complexed with various matrix
metalloproteinases. Additional biomarkers were considered with
which NT-proBNP and TIMP-1 could be compared; CRP and IL-6,
both markers of inﬂammation with strong reported predictive power
were chosen. CRP was determined by a highly sensitive, latex
particle-enhanced immunoassay (detection range of 0–20 mg/L,
Roche Diagnostics, Mannheim, Germany). High sensitivity IL-6 was
determined by an ELISA method (R&D Systems, Germany).
M.J. West et al 924
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 Statistical analysis
The present study was conducted in a nested case–control sample
including cases with a recurrent cardiovascular event (n ¼ 250) and
approximately matched controls for each case (n ¼ 250), using a
blood sample collected between 4 and 6 years after randomization.
Mean levels of continuous variables collected at randomization were
compared between cases and controls using a paired t-test, after
ﬁrst checking that there was no interaction between the effect of pra-
vastatin and status. For biomarker variables with a skewed distribution,
median values are presented and cases and controls were compared
using a Wilcoxon signed rank test. An independent sample t-test or
a Wilcoxon rank sum test was used to compare biomarker levels
between levels of other risk factors, within the control group. Spear-
man’s rank correlation was used to assess the relationship between
biomarker variables and baseline variables in the control group only.
Conditional logistic regression analysis for matched case-control
studies, matching cases and controls on the same amount of follow-up
time, was used to investigate the association between the outcome and
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 1 Characteristics of participants
Characteristics Controls (n 5 250) Cases (n 5 250) P-value
Age
a (years) 62 (53–68) 64 (59–68) ,0.001
Male sex 84 87 0.37
Body mass index (kg/m
2)2 6 +32 7 +4 0.001
SBP (mmHg) 134+19 137+19 0.04
DBP (mmHg) 81+10 82+10 0.08
History of
Hypertension 42 48 0.15
Diabetes mellitus 6 14 0.003
Smoking status
Never 34 24
Former 58 67 0.048
Current 8 9
Clinical data
Index ACS is MI 59 72 0.004
Reinfarction 7 20 ,0.001
Prior stroke 4 6 0.15
Prior CABG 31 31 1.0
Prior PTCA 15 13 0.44
Claudication 6 13 0.015
Score from LIPID risk model
b
6 (3–7) 7 (5–10) ,0.001
Lipid status
Total-cholesterol (mmol/L) 5.59+0.82 5.64+0.80 0.56
HDL-cholesterol (mmol/L) 0.93+0.20 0.94+0.24 0.47
Triglycerides (mmol/L) 1.73+0.77 1.90+1.02 0.04
Biomarkers
TIMP-1
a (ng/mL) 736 (647–842) 806 (704–931) ,0.001
C-reactive protein
a (mg/L) 2.7 (1.3–4.8) 3.1 (1.5–5.3) 0.20
NT-proBNP
a (pg/mL) 198 (93–416) 389 (152–864) ,0.001
IL-6 25 (20–32) 26 (21–33) 0.37
White cell count (1   10
9/L) 7.1+1.8 7.5+1.7 0.02
Concomitant medications
Aspirin 80 79 0.82
Beta blocker 48 48 0.86
Calcium channel blocker 29 38 0.046
Digoxin 6 11 0.08
Nitrate 28 36 0.054
ACE inhibitor 11 21 0.002
Data presented are percentages forcategorical variables, means+SD for normal continuous variables, and
amedian levels (1st and 3rd quartiles) for skewed continuous variables.
b
Marschner et al.
19
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 the explanatory variables. In these analyses, all the biomarkers were
treated as both continuous variables and as quartiles derived from
the distribution of the entire population. Four models were considered
for assessing the effect of NT-proBNP and TIMP-1: (1) individually as
unadjusted values; (2) individually, adjusted for treatment with pravas-
tatin and classical risk factors using the LIPID risk score
19 [that includes
13 components with differential weightings according to the import-
ance of the risk factor or the severity of the clinical presentation
(such as number of previous myocardial infarctions) at randomization];
(3) together with further adjustment for CRP and IL6, both as quartiles
and WBC; and (4) using a model in which the LIPID risk score was
replaced by age, multiple prior myocardial infarctions, diabetes melli-
tus, and prior stroke. The ﬁtted values from the conditional logistic
regression were plotted together with the Lowess smooth of these
values, and the shape of the smoothed plot was used to determine
the form of the relationship of WBC and the lipid risk score and
status. As the sample size was small and due to the matched design,
it was not possible to assess all of the standard risk factors for CVD
events simultaneously, so Model 4 was included, in order to account
for the four main baseline characteristics that differentiated cases
from controls. The test for trend associated with increasing quartiles
of TIMP-1 was estimated using the median for each quartile. Further,
the strengths of TIMP-1, NT-proBNP, IL6, and CRP for cardiovascular
risk prediction were compared. Conditional logistic regression models
were derived using the biomarkers as dichotomous variables and used
to explore to what extent NT-proBNP and TIMP-1 might add to the
predictive value of the strongest classical risk predictors.
P , 0.05 was considered to be signiﬁcant. Analyses were carried out
as both categorical and continuous variables with highly consistent
results and only the former is shown. All analyses were carried out
with SAS, version 9.1 (SAS Institute).
Results
The baseline characteristics of the study participants who sub-
sequently developed cardiovascular events (cases) and those
who remained free of reported cardiovascular events (controls)
are provided in Table 1. Overall, individuals who developed new
cardiovascular events were older, heavier, had higher blood press-
ures and were more likely to have diabetes and a previous history
of smoking. They were more likely to have had a myocardial infarct
and peripheral arterial disease and to have had multiple infarcts
prior to their initial randomization. There were no signiﬁcant
differences between the two groups for total and high-density lipo-
protein (HDL) cholesterol but plasma triglycerides were signiﬁ-
cantly higher among the cases.
Cardiovascular events
The nature of the events among cases subsequent to the blood
sample was as follows. Coronary deaths: 73 (29%); vascular non-
coronary deaths: 8 (3%); non-fatal myocardial infarctions: 112
(45%) and non-haemorrhagic stroke: 57 (23%) of cases.
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 2 Correlates of inﬂammatory markers in the control group
TIMP-1 (pg/mL) CRP (mg/L) NT-proBNP (pg/mL)
Panel A – Median levels of inﬂammatory markers
a
Diabetes No 736 2.52 200
Yes 709 3.26 159
P-value 0.74 0.26 0.45
Hypertension No 725 2.76 186
Yes 752 2.72 203
P-value 0.41 0.58 0.24
Smoking Never 746 2.37 203
Former 711 2.87 199
Current 760 3.03 128
P-value 0.48 0.22 0.20
Obesity No 730 2.51 191
Yes 754 3.72 255
P-value 0.26 0.06 0.36
Panel B – Spearman correlation coefﬁcients
b
Age 0.33
‡ 0.17
† 0.43
‡
Body mass index 0.04 0.11 20.02
Total-cholesterol 0.08 20.06 20.003
HDL-cholesterol 20.04 0.06 0.004
Triglycerides* 0.03 20.10 20.07
CRP 0.08 – 0.23
‡
NT-proBNP 0.34
‡ 0.23
‡ –
Median levels and correlation coefﬁcients of the control population are presented.
* P , 0.05,
† P , 0.01,
‡ P , 0.001.
aAccording to categorical risk factors.
bBetween inﬂammatory markers and continuous risk factors.
M.J. West et al 926
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 Traditional risk factors and N-terminal
pro-brain natriuretic peptide correlates
Circulating NT-proBNP levels for the entire group ranged
between 5 and 16 780 pg/mL with a mean value of 689 pg/mL
and a median value of 268 pg/mL (117–646, 25th and 75th percen-
tile). The corresponding values for TIMP-1 were 226 to 1654 pg/
mL with a mean of 798 (median 772 pg/mL; 25th–75th percentile
672–889 pg/mL). Treatment with pravastatin did not signiﬁcantly
change NT-proBNP or TIMP-1 levels (P ¼ 0.70 and 0.57 respect-
ively). As outlined in Table 2, neither NT-proBNP nor TIMP-1 con-
centrations in controls or cases were related to a history of
diabetes, hypertension, smoking status or adiposity (BMI).
TIMP-1 and NT-proBNP increased signiﬁcantly with age and with
CRP values.
The CRP and IL-6 concentrations are shown in Table 1 and
neither differed signiﬁcantly between cases and controls.
N-terminal pro-brain natriuretic
peptide and tissue inhibitor of
metalloproteinase-1 concentrations
and cardiovascular risk
The concentrations of both NT-proBNP and TIMP-1 were signiﬁ-
cantly higher among the cases who experienced a recurrent cardi-
ovascular event during follow-up than among those who did not
(389 vs.198 pg/mL for NT-proBNP; 808 vs. 736 pg/mL for
TIMP-1; P , 0.001 for both; Table 1). As outlined in Table 3, the
odds ratio (OR) of recurrent cardiovascular events with increasing
quartiles of NT-proBNP and TIMP-1 (Model 1; P for
trend,0.0001) were such that individuals in the highest quartile
had a risk about three times higher than those in the lowest quar-
tile (for NT-proBNP 95% CI 1.8–5.1; for TIMP-1 1.6–4.7; P ,
0.001 for both).
The relationships between plasma NT-proBNP and TIMP-1 con-
centrations and risk of recurrent cardiovascular events were vir-
tually unaltered in analyses that adjusted for both treatment with
pravastatin and baseline differences of traditional risk factors
according to the LIPID risk score (Model 2; P for trend , 0.001,
Table 3). After further adjustment for CRP and IL-6 the relationship
between NT-proBNP and TIMP-1 and future recurrent cardiovas-
cular events remained independently signiﬁcant (P for
trend , 0.004 and 0.018 respectively, Model 3). The relationships
were unchanged with WBC count in the model. Model 4
resembles Model 3 except that the LIPID score was replaced by
the main components that differed signiﬁcantly between cases
and controls, namely age, multiple prior myocardial infarctions, dia-
betes mellitus and stroke. None of these potential confounders
altered the independent relationships between NT-proBNP or
TIMP-1 and combined cardiovascular events (P for trend ¼ 0.023
and 0.02 respectively).
...................................................... ......................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 3 Odds ratio for combined cardiovascular events according to levels of N-terminal pro-brain natriuretic peptide
(NT-proBNP) and tissue inhibitor of metalloproteinase-1 (TIMP-1)
Quartile
NT-proBNP (pg/mL)
P for trend
TIMP-1 (pg/mL)
P for trend
No. (%) CV events <117 117–268 268–646 >646 <672 672–771 771–888 >888
1 234 1 234
51 (40) 50 (40) 64 (51) 85 (69) 46 (37) 56 (45) 73 (58) 75 (61)
Model 1
Odds ratio 1.00 0.98 1.44 3.02 1.00 1.45 2.39 2.77
95% CI – 0.59–1.64 0.84–2.47 1.78–5.10 ,0.001 – 0.88–2.38 1.43–3.98 1.63–4.72 ,0.0001
P-value – 0.95 0.18 ,0.001 – 0.14 ,0.0001 ,0.0001
Model 2
Odds ratio 1.00 1.02 1.27 2.69 1.00 1.30 2.04 2.23
95% CI – 0.59–1.77 0.72–2.23 1.54–4.71 ,0.001 – 0.77–2.19 1.19–3.52 1.26–3.94 0.002
P-value – 0.94 0.41 ,0.001 – 0.33 0.01 0.006
Model 3
Odds ratio 1.00 0.92 1.16 2.33 1.00 1.27 1.92 1.99
95% CI – 0.52–1.62 0.64–2.10 1.28–4.24 0.004 – 0.74–2.19 1.10–3.38 1.09–3.64 0.018
P-value – 0.77 0.62 0.005 – 0.39 0.023 0.025
Model 4
Odds ratio 1.00 0.91 1.04 2.22 1.00 1.19 2.03 1.88
95% CI – 0.50–1.64 0.55–1.97 1.15–4.29 0.023 – 0.67–2.12 1.13–3.65 0.99–3.58 0.020
P-value – 0.75 0.91 0.018 – 0.55 0.018 0.053
Model 1: crude analysisfor biomarkers separately; Model 2: biomarkers separately,adjusted for treatment with pravastatin and the LIPID risk score; Model 3: has both NT-proBNP
and TIMP-1, adjusted for the LIPID risk score, white blood cell count and treatment with pravastatin, with additional adjustment for CRP and IL6 ﬁtted as quartiles; Model 4: similar
to Model 3, with the LIPID risk score replaced by age, multiple prior myocardial infarctions, diabetes mellitus and prior stroke.
TIMP-1, NT-proBNP, and cardiovascular outcomes 927
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 As shown in Figure 1, neither CRP nor IL-6 was independently
associated with increased risk of cardiovascular events.
Wefurtherexploredtowhatextentthetwobiomarkersmayadd
to the predictive value of the strongest classical lipid predictor, the
total cholesterol/HDL-cholesterol ratio or to that of CRP and IL-6
(Table 4). In these analyses, subjects were classiﬁed as being below
orabovethemedianforanyoftheriskfactorsconsidered.Increased
risk of a cardiovascular event was associated with higher levels of
NT-proBNP (panels A, B, and E) and with higher levels of TIMP-1
(panelsC,D,andF).NT-proBNPandTIMP-1eachaddedtothepre-
dictive effect of the total/HDL cholesterol ratio and their respective
effectsremainedsigniﬁcantindependentlyofeachother.Theresults
were essentially unchanged after adjustment for treatment.
Analyses of other potential confounders
To place the predictive value of the biomarkers NT-proBNP and
TIMP-1 into the context of that obtained from measurements of
inﬂammatory biomarkers other than C-reactive protein, additional
analyses were performed (Figure 1). Comparing the fourth vs. the
ﬁrst quartiles, and adjusting for traditional risk factors, NT-proBNP
(OR 2.33, 95% CI 1.30–4.17; P ¼ 0.005) and TIMP-1 (OR 2.05,
95% CI 1.13–3.71; P ¼ 0.02) remained independently associated
with future cardiovascular risk. Similarly, the relative risk across
the quartiles of TIMP-1, which alone was 8.5 (95% CI 3–24; P ,
0.001), remained unchanged when WBC count was included and
declined only slightly but not signiﬁcantly when both WBC
count and LIPID score were included (OR 5.8; 95% CI 1.9–17.5;
P ¼ 0.002).
Discussion
The present ﬁndings demonstrate that two biomarkers that have
several important cardiovascular functional similarities were
strongly and independently associated with increased risk of
future cardiovascular events in a population of subjects with pre-
ceding stable clinical CHD. Both TIMP-1 and BNP raised the risk
between two and three-fold even after adjusting for a comprehen-
sive set of conventional risk factors, a set of components that dif-
fered signiﬁcantly between cases and controls, treatment with a
statin and three other established biomarkers CRP, IL-6, and
WBC count.
BNP or NT-proBNP measurements are prognostic during acute
myocardial infarction (MI)
20 and during non-MI episodes of acute
coronary syndrome.
21 This is likely to be largely due to the associ-
ated haemodynamic changes, although ischaemia may augment
BNP expression.
22 Inﬂammatory markers such as TIMP-1 are
also promising prognostic markers in the setting of acute coronary
syndrome because they mirror the extent of acute tissue damage.
In the non-acute setting inﬂammatory markers such as TIMP-1 may
be prognostic because they reﬂect factors that inﬂuence the pro-
gression of athero-thrombotic plaques. Furthermore TIMP-1 has
also been implicated in processes that are involved in ventricular
re-modelling
6 and may be predictive of chronic heart failure.
23,24
Patients with recurrent CVD events had signiﬁcantly higher
plasma NT-proBNP levels than patients who remained free from
future events. Kragelund et al.
15 reported a similar association
between NT-proBNP and mortality that was independent of
other risk factors, in patients with stable CHD. Similar ﬁndings
have been reported by Omland et al.
25 A recent report by Blan-
kenberg et al.
14 has conﬁrmed the importance of NT-proBNP as
an independent and robust predictor of future events in the
heart outcomes prevention evaluation (HOPE) study. These ﬁnd-
ings are consistent with the concept that post-MI impairment of
myocardial function proportionally increases NT-proBNP levels
and worsens prognosis for recurrent CVD events. Our data are
also consistent with previous reports of higher circulating
TIMP-1 levels shortly after episodes of acute coronary syn-
dromes.
16,17 Recently, Cavusoglu et al.
18 reported that TIMP-1 pre-
dicted cardiovascular episodes and death during 2 years of
observation after coronary angiography and Lubos et al.
26
Figure 1 Odds ratio (OR) and 95% conﬁdence intervals for
cardiovascular events associated with the upper compared with
the lower quartile level of biomarkers. Model 1: unadjusted
ORs. Model 2: includes adjustment for treatment with pravastatin
and the LIPID risk score
12. Model 3: includes adjustment for all
confounders. Model 4: includes adjustment for all confounders,
but the LIPID score was replaced by four major factors (age, mul-
tiple prior myocardial infarctions, diabetes, and prior stroke) that
differed signiﬁcantly between cases and controls. CI, conﬁdence
interval; NT-proBNP, N-terminal pro-brain natriuretic peptide;
TIMP-1, tissue inhibitor of metalloproteinase-1; LIPID, long-term
intervention with pravastatin in ischaemic disease study.
M.J. West et al 928
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 observed higher levels of TIMP-1 in those patients with suspected
coronary artery disease who subsequently experienced cardiovas-
cular death compared with those who did not. However the
present study is the ﬁrst to have shown TIMP-1 to be an indepen-
dent predictor of cardiovascular events in patients with stable
ischaemic heart disease. Remodelling of atherosclerotic arteries
and of the damaged myocardium, as well as plaque rupture
involves degradation of extracellular matrix by metalloproteinases,
a process that is opposed by TIMPs.
11
Several TIMPs are expressed in myocardium
8 and genetic del-
etion of TIMP-1 demonstrates its role in maintaining ventricular
geometry and function.
27 On the other hand, adequate manage-
ment of risk factors including diabetes mellitus leads to lower cir-
culating levels of TIMP-1.
28 We postulate that the increased
concentrations of TIMP-1 found in plasma in these disease pro-
cesses reﬂect a compensatory response to degradative
inﬂammatory enzymes. We had selected to study TIMP-1 from
among other circulating TIMPs because more is known about it.
Previous CVD is one of the strongest risk factors for future
CVD events because it demonstrates that the patients in question
are susceptible to their risk factor proﬁle and the disease process.
Risk stratiﬁcation in a population with increasing need of secondary
prevention is still a challenge. Amongst those who have suffered
previous CVD, impaired ventricular function as well as plasma
levels of NT-proBNP are particularly powerful predictors of recur-
rent CVD events.
29 The results of the present study show that
patients who suffered recurrent CVD events were more likely to
have had myocardial infarction (MI), especially recurrent infarc-
tions, as the qualifying criterion for the presence of ischaemic
heart disease. Nevertheless, neither multiple previous infarctions
nor the presence of other risk factors (age, diabetes, overweight
and a conventional risk proﬁle) inﬂuenced the independent
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 4 Odds ratio for cardiovascular events according to levels of N-terminal pro-brain natriuretic peptide
(NT-proBNP) and total cholesterol/high-density lipoprotein (HDL)-cholesterol ratio (Panel A), C-reactive protein (Panel
B), tissue inhibitor of metalloproteinase-1 (TIMP-1) and total cholesterol/HDL-cholesterol ratio (Panel C), C-reactive
protein (Panel D), and NT-proBNP and TIMP-1 (Panel E), above (1) or below (2) the median
Panel A
NT-proBNP TC:HDL-C Odds ratio 95% CI P-value P-value for interaction
22 1.00 –
þ 2 2.58 1.51–4.41 ,0.001
2 þ 1.61 0.95–2.74 0.08
þþ 3.07 1.77–5.33 ,0.001 0.43
Panel B
NT-proBNP CRP Odds ratio 95% CI P-value
22 1.00 –
þ 2 2.66 1.57–4.50 ,0.001
2 þ 1.43 0.86–2.38 0.17
þþ 2.37 1.45–3.88 ,0.001 0.20
Panel C
TIMP-1 TC:HDL-C Odds ratio 95% CI P-value P-value for interaction
22 1.00 –
þ 2 1.62 0.99–2.66 0.055
2 þ 0.99 0.60–1.62 0.96
þþ 2.72 1.62-4.58 ,0.001 0.15
Panel D
TIMP-1 CRP Odds ratio 95% CI P-value
22 1.00 –
þ 2 1.85 1.09–3.12 0.022
2 þ 1.12 0.68–1.85 0.67
þþ 2.55 1.53–4.27 ,0.001 0.57
Panel E
NT-proBNP TIMP-1 Odds ratio 95% CI P-value
22 1.00 –
þ 2 2.07 1.19–3.59 0.010
2 þ 2.00 1.16–3.44 0.013
þþ 3.48 2.13–5.66 ,0.001 0.66
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 associations between future cardiovascular events and
NT-proBNP and TIMP-1 (Model 4 in Table 3).
The positive association between NT-proBNP and high sensi-
tivity C-reactive protein (CRP) demonstrated a potential inter-
action between natriuretic peptides and inﬂammatory markers,
but CRP was not predictive of recurrent CVD. The reason for
the superiority of TIMP-1 over CRP is uncertain but in a recent
report by Blankenberg et al.
14 in which NT-proBNP was found
to predict future events in the HOPE study, CRP was also found
to be non-predictive. Increased circulating IL-6, an inﬂammatory
interleukin that has also been identiﬁed as predicting future cardi-
ovascular events
30 or progression of atherosclerosis
31 was found in
this study, as with CRP not to reduce the strengths of the associ-
ations between future events and the concentrations of
NT-proBNP and TIMP-1. Despite the potential interaction
between the two biomarkers TIMP-1 and NT-proBNP remained
independent in risk prediction, suggesting that their combined
use may further enhance the assessment of the risk of recurrent
CVD. Comparing both markers, NT-proBNP appeared to be the
more powerful.
Pravastatin therapy did not alter NT-proBNP or TIMP-1 levels.
On one hand, lower NT-proBNP levels might have been expected
in the pravastatin group because the LIPID trial results included a
22% lower rate of death from cardiac failure following pravastatin
treatment.
4 Many beneﬁcial effects of statins in CHD have been
demonstrated beyond cholesterol lowering. They have been
shown to improve endothelial function, to exhibit anti-
inﬂammatory properties, and to prevent cardiac hypertrophy.
Their potential to decrease oxidative stress
32 may attenuate left
ventricular remodelling and thus reduce NT-proBNP levels. On
the other hand increased concentrations of TIMP-1 have been
found in carotid plaques following pravastatin treatment.
33
Overall the predictive power of NT-proBNP for recurrent CV
events seems to be independent of statin intake.
7
Two important limitations should be kept in mind. First,
although the sample size was relatively small, the robustness of
the predictive power of the two biomarkers that were the
subject of the primary analysis, argues strongly for the validity of
the ﬁndings. The associations between TIMP-1 and BNP and
future CVD events remained in a multivariable model that
included conventional risk factors, severity of disease and two
additional biomarkers that have also been reported to be strongly
predictive.
Second, the LIPID trial design did not include objective measure-
ments of left ventricular dysfunction and heart failure. Since both
BNP and TIMP-1 are associated with heart failure and left ventricu-
lar remodelling the association of these biomarkers with future
CVD events may have partly reﬂected greater prevalence of
patients with heart failure among cases. While this would be con-
sistent with the greater number of patients with multiple previous
myocardial infarctions among cases than controls, the LIPID score
does account for the presence of multiple risk factors.
34
This study strongly supports the use of plasma TIMP-1 and
NT-proBNP for prognostic purposes. Since statin therapy had no
effect on either TIMP-1 or NT-proBNP levels additional studies
are required to identify interventions that may address this risk
in a more direct manner.
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